MARKET

XRTX

XRTX

Xortx Therapeutics Inc
NASDAQ
0.5620
+0.0020
+0.36%
After Hours: 0.5600 -0.002 -0.36% 19:59 12/31 EST
OPEN
0.6000
PREV CLOSE
0.5600
HIGH
0.6000
LOW
0.5600
VOLUME
44.25K
TURNOVER
--
52 WEEK HIGH
1.790
52 WEEK LOW
0.5100
MARKET CAP
3.91M
P/E (TTM)
-1.1887
1D
5D
1M
3M
1Y
5Y
1D
XORTX Leans Into Genetic Breakthroughs in Gout as It Reshapes Board and Advances Oxypurinol
TipRanks · 12/31/2025 23:37
XORTX Awaits ASX Decision on Closing Vectus Renal Program Acquisition
Reuters · 12/31/2025 23:15
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
Barchart · 12/31/2025 17:15
Weekly Report: what happened at XRTX last week (1222-1226)?
Weekly Report · 12/29/2025 10:25
Weekly Report: what happened at XRTX last week (1215-1219)?
Weekly Report · 12/22/2025 10:25
Weekly Report: what happened at XRTX last week (1208-1212)?
Weekly Report · 12/15/2025 10:33
Weekly Report: what happened at XRTX last week (1201-1205)?
Weekly Report · 12/08/2025 10:32
Weekly Report: what happened at XRTX last week (1124-1128)?
Weekly Report · 12/01/2025 10:27
More
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

Webull offers XORTX Therapeutics Inc stock information, including NASDAQ: XRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XRTX stock methods without spending real money on the virtual paper trading platform.